Drug intelligence / Profile preview

[1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule with the chemical formula C27H29N3O5 and a molecular weight of approximately 475.54 g/mol[6][8]. It is classified as an experimental drug and belongs to the class of organic compounds known as phenylalanine derivatives[2]. The structure features two phenylethylene groups, a hydroxy group, and a pyridine-containing carbamate moiety. There are no approved medical indications or clinical trial data available for this compound, and its mechanism of action has not been described in public databases. It appears in pharmaceutical research libraries such as ZINC15 but does not have evidence of development beyond early-stage research or screening[1][7].

Other names
N-[(3S)-1-hydroxy-2-oxo-5-phenyl–3-pentanyl]-Nalpha–[(3-pyridinylmethoxy)carbonyl]–L–phenylalaninamide(pyridin–3–yl)methyl N–((1S)–1––((3S)–1-hydroxy−2−oxo−5−phenylpentan−3−yl)carbamoyl)—2—phenylethyl)carbamate(pyridin–3— yl)methyl N—[(1S)— 1-{[(3S)— 1—hydroxy— 2— oxo —5 — phen yl pentan — 3 — yl ] carbamoyl } – 2 – phenyleth yl ] carbamate

Beyond the preview

Go deeper on [1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call